Table of Contents

Acknowledgments
Preface

PART 1: THE ECONOMICS OF PRESCRIPTION DRUGS

Chapter 1: Introduction
Chapter 2: The prescription drug market
Chapter 3: Proposed solutions for rising drug prices
Chapter 4: Measuring the value of prescription drugs

PART 2: EXPERIENCES MEASURING A DRUG'S VALUE IN THE US AND ABROAD

Chapter 5: Measuring drug value: Whose job is it anyway?
Chapter 6: Institute for Clinical and Economic Review (ICER)
Chapter 7: Other US value assessment frameworks
Chapter 8: Do drugs for special populations warrant higher prices?

PART 3: GETTING TO VALUE-BASED PRICING FOR DRUGS

Chapter 9: Improving value measurement
Chapter 10: Aligning prices with value
Chapter 11: The path forward

Index

About the Author

Peter J. Neumann, ScD, is Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. Dr. Neumann is also a member of the editorial advisory board of Health Affairs and the health policy advisory board for the Congressional Budget Office.

Joshua T. Cohen, PhD, is Deputy Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Research Associate Professor of Medicine at Tufts University School of Medicine.

Daniel A. Ollendorf, PhD, is Director of Value Measurement and Global Health Initiatives at the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Research Assistant Professor of Medicine at Tufts University School of Medicine. Prior to joining CEVR, he spent ten years as the Chief Scientific Officer at the Institute for Clinical and Economic Review (ICER). Dr. Ollendorf
currently serves as a non-resident Fellow at the Center for Global Development, and as Chair of the Health Technology Assessment International (HTAi) Global Policy Forum.

Reviews

"This is a must-read guide for both insiders and non-experts to a topic that will be at the forefront of the drug pricing debate in the coming decade." -- Frank S. David, MD, PhD, shepherd.com
"An extremely helpful and well-sourced guide to the myriad thorny issues and history behind current drug pricing and value assessment." --Austin Frakt, Boston University School of Public Health
"The pricing of medicines is one of the hardest problems in public policy, brimming with clinical and economic complexity. This remarkable book written by the world's leading group on drug pricing explains the key issues clearly, and without compromise. If you read only one book on how to price medicines smartly, this should be the one." --Amitabh Chandra, Harvard Kennedy School of Government and Harvard Business School
"This is a highly readable and timely guide for anyone interested in thoughtful solutions to the nation's ongoing debates about prescription drug pricing, controlling costs, and ensuring affordability while enhancing innovation to improve people's health." --Mark McClellan, Founding Director of the Margolis Center for Health Policy at Duke University, former administrator of CMS, and former commissioner of the FDA